Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as ...
Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...
Zacks Investment Research on MSN
Denali enters into a $275M funding deal with Royalty Pharma
Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies are acting as joint book running managers for the offering. Published first on TheFly – the ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
In early December 2025, Denali Therapeutics announced a US$275 million synthetic royalty funding agreement with Royalty Pharma tied to future worldwide net sales of its investigational Hunter syndrome ...
Investing.com -- Denali Therapeutics Inc. (NASDAQ:DNLI) stock dropped 7.2% in after-hours trading on Tuesday after the company announced plans to offer $200 million of common stock and pre-funded ...
GlobalData on MSN
Denali makes $275m funding agreement with Royalty Pharma
Completion of the agreement remains contingent on several closing conditions.
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...
Rescue urgently needed for Denali, a 2-year-old Mastiff awaiting safe foster placement OCEAN COUNTY, NJ – A plea for help has ...
The luxury GMC Denali EV returns for 2026 after its 2024 debut. It is now joined by the lower-cost Elevation and the off-road ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results